COVID-19 Vaccine Safety First Year Findings in Adolescents.

Elisabeth M Hesse,Anne Hause,Tanya Myers,John R Su,Paige Marquez,Bicheng Zhang,Margaret M Cortese,Andrea Thames-Allen, Christine R Curtis,Susan A Maloney,Deborah Thompson,Narayan Nair,Meghna Alimchandani,Manette Niu,Julianne Gee,David K Shay,Tom T Shimabukuro

Pediatrics（2023）

引用 0|浏览14

暂无评分

摘要

During the first year BNT-162b2 was administered to adolescents ages 12 to 17 years, most reported adverse events were mild and appeared self-limited. Rates of myocarditis were lower than earlier reports. No new serious safety concerns were identified.

查看译文

关键词

adolescents

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要